Related Experiment Video
Updated: Mar 7, 2026
08:45
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
14.2K
SLC12A3 variants modulate LDL cholesterol levels in the Mongolian population
Caiyan An1, Kejin Zhang2, Xiulan Su3
1Clinical Research Center of the Affiliated Hospital, Inner Mongolia Medical University, Hohhot, 010050, Inner Mongolia, China.
Lipids in Health and Disease
|February 8, 2017
Summary
Genetic variants in the SLC12A3 gene are linked to abnormal low-density lipoprotein cholesterol (LDL-c) levels in the Mongolian population. This finding highlights a potential genetic susceptibility to dyslipidemia in this ethnic group.
Area of Science:
- Genetics
- Metabolic Disorders
- Cardiovascular Disease Pathogenesis
Background:
- Lipid metabolism abnormalities are key contributors to cardiovascular disease (CVD) development.
- Genetic variations are known risk factors for dyslipidemia.
- The specific role of SLC12A3 gene variants in Mongolian lipid metabolism was previously uninvestigated.
Purpose of the Study:
- To investigate the association between SLC12A3 gene variants and lipid profiles in the Mongolian population.
- To determine the impact of SLC12A3 variants on total cholesterol, triglycerides, LDL-c, and HDL-c levels.
Main Methods:
- Analysis of a randomly selected Mongolian population sample (n=331) from China.
- Utilized ANOVA, Kruskal-Wallis H test, and haplotype analysis to assess lipid levels and SLC12A3 polymorphisms.
- Examined associations between specific single nucleotide polymorphisms (SNPs) and lipid parameters.
Main Results:
- Three SLC12A3 SNPs (rs5803, rs2010501, rs711746) were significantly associated with serum low-density lipoprotein cholesterol (LDL-c) levels (p < 0.01).
- Haplotype analysis corroborated the association between SLC12A3 variants and LDL-c levels.
- The influence of SLC12A3 polymorphisms on LDL-c remained significant after adjusting for non-genetic factors.
Conclusions:
- Variants of the SLC12A3 gene are associated with an increased susceptibility to abnormal serum LDL-c levels in the Mongolian population.
- These findings suggest SLC12A3 as a potential genetic marker for dyslipidemia risk in this demographic.
Related Concept Videos
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
85
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
85
01:29Pharmacogenomics: Identification of New Drug Targets
56
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
56
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
76
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
76
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
60
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
01:27Principles of Pharmacogenetics: Types of Genetic Variants
67
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
67
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K